301 – 310 of 350
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
- Contribution to journal › Article
-
Mark
Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer
- Contribution to journal › Article
-
Mark
Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
- Contribution to journal › Article
-
Mark
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.
- Contribution to journal › Article
-
Mark
Hormone therapy: Improving therapy decisions and monitoring
- Contribution to journal › Article
-
Mark
CYSTATIN C AND NEUROENDOCRINE DIFFERENTIATION IN THE MALE REPRODUCTIVE SYSTEM AND IN PROSTATE CANCER
(2006)
- Thesis › Doctoral thesis (compilation)
-
Mark
The Prostate Cancer Prevention Trial and its implications for clinical practice: A European consensus
- Contribution to journal › Article
-
Mark
Solution structures of human and porcine beta-microseminoprotein
- Contribution to journal › Article
- 2005
-
Mark
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue
- Contribution to journal › Article
-
Mark
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
- Contribution to journal › Article
